Think Deeply, Think Well

Founded by Drs. Sara and Jack Gorman, authors of the revolutionary new title ‘Denying to the Grave’, Critica is a community committed to making rational decisions about health and security. In a culture dominated by polarizing politics, and an abundance of unchecked misinformation, Critica exists to revolutionize the role of science in making rational health decisions.

Critica is a non-profit organization that was created to carry out the suggestions for counteracting science denial that were made in Denying to the Grave. Today, Critica strives to publish articles and commentaries that explore the roots of science denial as it pertains to health and safety. The Critica team is comprised of experts in medicine, sociology, psychology, public health, and neuroscience who believe that everyone, everywhere is capable of making rational decisions about health and safety if provided with sufficient information in an understandable format. Critica also develops and tests new methods of counteracting misinformation about health and science and advocates for the inclusion of scientific evidence in public policymaking. We invite all people who are concerned about scientific evidence, accuracy, and correct information about health to join us.

Critica has received a new grant from Cornell University’s Center for Social Sciences to pursue our work on counteracting online misinformation about COVID-19 vaccines.


Critica CMO David Scales takes care of patients with COVID-19 on a regular basis. He recently sat down with our COO Catherine DiDesidero to describe his experiences on the front-line of patient care. You can listen to the interview here.

Critica welcomes our new Infodemiologists, Lindsay Hurth and Julia Florman. Lindsay and Julia will participate in our current Robert Wood Johnson Foundation-funded grant to counteract online misinformation about COVID-19 vaccines . 


  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey


Critica, Inc.

2700 Arlington Avenue

Bronx, NY 10463

Media Inquiries:

Catherine DiDesidero


Critica, Inc.